{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:34:17Z","timestamp":1772516057986,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Oncological treatments are known to induce cardiac toxicity, but the impact of new-onset cancer in patients with pre-existing HF remains unknown. This review focuses on the epidemiology, pathophysiological mechanisms, and clinical implications of HF patients who develop malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Novel findings suggest that HF and cancer, beside common risk factors, are deeply linked by shared pathophysiological mechanisms. In particular, HF itself may enhance carcinogenesis by producing pro-inflammatory cytokines, and it has been suggested that neurohormonal activation, commonly associated with the failing heart, might play a pivotal role in promoting neoplastic transformation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>The risk of malignancies seems to be higher in HF patients compared to the general population, probably due to shared risk factors and common pathophysiological pathways. Additionally, management of these patients represents a challenge for clinicians, considering that the co-existence of these diseases significantly worsens patients\u2019 prognosis and negatively affects therapeutic options for both diseases.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11897-021-00517-y","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T04:02:45Z","timestamp":1624852965000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-2865","authenticated-orcid":false,"given":"Alessandra","family":"Cuomo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Paudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carannante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Iengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018;20:879\u201387.","journal-title":"Eur J Heart Fail"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1089\/ars.2016.6930","volume":"30","author":"CG Tocchetti","year":"2019","unstructured":"\u2022\u2022 Tocchetti CG, Cadeddu C, Di Lisi D, et al. From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview. Antioxid Redox Signal. 2019;30:2110\u201353 Interesting review summarizing known pathophysiological mechanisms of cardiotoxicity.","journal-title":"Antioxid Redox Signal"},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11912-020-00990-z","volume":"23","author":"A Cuomo","year":"2020","unstructured":"Cuomo A, Pirozzi F, Attanasio U, et al. Cancer risk in the heart failure population: epidemiology, mechanisms, and clinical implications. Curr Oncol Rep. 2020;23:7.","journal-title":"Curr Oncol Rep"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","volume":"22","author":"RA de Boer","year":"2020","unstructured":"de Boer RA, Hulot J-S, Tocchetti CG, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:2272\u201389.","journal-title":"Eur J Heart Fail"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1113\/JP276746","volume":"598","author":"M Brancaccio","year":"2020","unstructured":"Brancaccio M, Pirozzi F, Hirsch E, Ghigo A. Mechanisms underlying the cross-talk between heart and cancer. J Physiol. 2020;598:3015\u201327.","journal-title":"J Physiol"},{"key":"517_CR6","doi-asserted-by":"publisher","unstructured":"\u2022 Tini G, Bertero E, Signori A, Sormani MP, Maack C, De Boer RA, et al. Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis. J Am Heart Assoc. 2020. https:\/\/doi.org\/10.1161\/JAHA.119.016309Interesting meta-Analysis exploring cancer mortality on patients affected by heart failure with reduced ejection fraction.","DOI":"10.1161\/JAHA.119.016309"},{"key":"517_CR7","doi-asserted-by":"publisher","unstructured":"\u2022 Ameri P, Canepa M, Luigi Nicolosi G, Marchioli R, Latini R, Tavazzi L, et al. Cancer in chronic heart failure patients in the GISSI-HF trial. Eur J Clin Investig. 2020. https:\/\/doi.org\/10.1111\/eci.13273In this manuscript the Authors explore the incidence of cancer in the population enrolled in the GISSI-HF trial.","DOI":"10.1111\/eci.13273"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","volume":"62","author":"T Hasin","year":"2013","unstructured":"Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, et al. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol. 2013;62:881\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.amjmed.2017.02.024","volume":"130","author":"T Hasin","year":"2017","unstructured":"\u2022 Hasin T, Iakobishvili Z, Weisz G. Associated risk of malignancy in patients with cardiovascular disease: evidence and possible mechanism. Am J Med. 2017;130:780\u20135 In this study the Authors confirm that patients with heart failure present higher risk of developing malignancies.","journal-title":"Am J Med"},{"key":"517_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","volume":"68","author":"T Hasin","year":"2016","unstructured":"Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol. 2016;68:265\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.472","volume":"18","author":"A Banke","year":"2016","unstructured":"\u2022 Banke A, Schou M, Videbaek L, M\u00f8ller JE, Torp-Pedersen C, Gustafsson F, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail. 2016;18:260\u20136 In this interesting study the Authors demonstrated that patients with heart failure, compared to controls, presented higher risk of incident cancer and also, when matched for sex and age, higher risk of death.","journal-title":"Eur J Heart Fail"},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/hr.2017.45","volume":"40","author":"M Sakamoto","year":"2017","unstructured":"Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, et al. Does the pathophysiology of heart failure prime the incidence of cancer? Hypertens Res. 2017;40:831\u20136.","journal-title":"Hypertens Res"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijcard.2020.05.035","volume":"316","author":"B Schwartz","year":"2020","unstructured":"Schwartz B, Schou M, Gislason GH, K\u00f8ber L, Torp-Pedersen C, Andersson C. Prevalence and incidence of various cancer subtypes in patients with heart failure vs matched controls. Int J Cardiol. 2020;316:209\u201313.","journal-title":"Int J Cardiol"},{"key":"517_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jacc.2018.01.069","volume":"71","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S, Bhatt DL, Claggett B, Djouss\u00e9 L, Shah SJ, Chen J, et al. Lack of association between heart failure and incident cancer. J Am Coll Cardiol. 2018;71:1501\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jacc.2018.02.015","volume":"71","author":"P Boffetta","year":"2018","unstructured":"Boffetta P, Malhotra J. Impact of heart failure on cancer incidence: a complicated question. J Am Coll Cardiol. 2018;71:1511\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR16","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Moon JM, Lee HJ, Han K, et al. Occult blood in feces is associated with an increased risk of ischemic stroke and myocardial infarction: a nationwide population study. J Am Heart Assoc. 2021. https:\/\/doi.org\/10.1161\/JAHA.120.017783In this recent manuscript the Authors demonstrated that the presence of occult fecal blood is associated with higher risk of myocardial infarction and ischemic stroke, regardless of anemia and colon cancer diagnosis.","DOI":"10.1161\/JAHA.120.017783"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/ejhf.1539","volume":"21","author":"RA de Boer","year":"2019","unstructured":"de Boer RA, Meijers WC, Meer P, Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21:1515\u201325.","journal-title":"Eur J Heart Fail"},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","volume":"41","author":"L Liberale","year":"2020","unstructured":"\u2022\u2022 Liberale L, Montecucco F, Tardif J-C, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur Heart J. 2020;41:2974\u201382 In this interesting manuscript the Authors discuss the relationship between ageing, oxidative stress, cancer and cardiovascular diseases.","journal-title":"Eur Heart J"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/antiox9070641","volume":"9","author":"V Mercurio","year":"2020","unstructured":"Mercurio V, Cuomo A, Cadeddu Dessalvi C, et al. Redox imbalances in ageing and metabolic alterations: implications in cancer and cardiac diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). Antioxidants. 2020;9:641.","journal-title":"Antioxidants"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman ND. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737\u201345.","journal-title":"JAMA"},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1001\/jama.294.12.1505","volume":"294","author":"NS Godtfredsen","year":"2005","unstructured":"Godtfredsen NS. Effect of smoking reduction on lung cancer risk. JAMA. 2005;294:1505\u201310.","journal-title":"JAMA"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/cvr\/cvz035","volume":"115","author":"WC Meijers","year":"2019","unstructured":"Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115:844\u201353.","journal-title":"Cardiovasc Res"},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and cancer \u2014 viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794\u20138.","journal-title":"N Engl J Med"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","volume":"29","author":"MF Gregor","year":"2011","unstructured":"Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415\u201345.","journal-title":"Annu Rev Immunol"},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377\u201385.","journal-title":"Eur Heart J"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12885-017-3696-4","volume":"17","author":"P Ballotari","year":"2017","unstructured":"Ballotari P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Greci M, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017;17:703.","journal-title":"BMC Cancer"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","volume":"138","author":"E Bertero","year":"2018","unstructured":"Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. 2018;138:735\u201342.","journal-title":"Circulation"},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4161\/cbt.10.1.11944","volume":"10","author":"D Zhang","year":"2010","unstructured":"Zhang D, Yong Ma Q, Hu H-T, Zhang M. \u03b2 2 -adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-\u03baB and AP-1. Cancer Biol Ther. 2010;10:19\u201329.","journal-title":"Cancer Biol Ther"},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature10368","volume":"477","author":"MR Hara","year":"2011","unstructured":"Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, et al. A stress response pathway regulates DNA damage through \u03b22-adrenoreceptors and \u03b2-arrestin-1. Nature. 2011;477:349\u201353.","journal-title":"Nature"},{"key":"517_CR30","doi-asserted-by":"publisher","unstructured":"Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013. https:\/\/doi.org\/10.1172\/JCI63324.","DOI":"10.1172\/JCI63324"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1172\/JCI40802","volume":"120","author":"AK Sood","year":"2010","unstructured":"Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010;120:1515\u201323.","journal-title":"J Clin Invest"},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","volume":"5","author":"E Bertero","year":"2019","unstructured":"Bertero E, Ameri P, Maack C. Bidirectional relationship between cancer and heart failure: old and new issues in cardio-oncology. Card Fail Rev. 2019;5:106\u201311.","journal-title":"Card Fail Rev"},{"key":"517_CR33","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jcp.24260","volume":"228","author":"MR Galdiero","year":"2013","unstructured":"Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2013;228:1404\u201312.","journal-title":"J Cell Physiol"},{"key":"517_CR34","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.4049\/jimmunol.160.7.3251","volume":"160","author":"G Shakhar","year":"1998","unstructured":"Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol. 1998;160:3251\u20138.","journal-title":"J Immunol"},{"key":"517_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD. The renin\u2013angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745\u201359.","journal-title":"Nat Rev Cancer"},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"K Egami","year":"2003","unstructured":"Egami K, Murohara T, Shimada T, Sasaki KI, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67\u201375.","journal-title":"J Clin Invest"},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","volume":"167","author":"K-L Wang","year":"2013","unstructured":"Wang K-L, Liu C-J, Chao T-F, Huang C-M, Wu C-H, Chen T-J, et al. Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol. 2013;167:2162\u20136.","journal-title":"Int J Cardiol"},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"e6394","DOI":"10.1097\/MD.0000000000006394","volume":"96","author":"H Sun","year":"2017","unstructured":"\u2022 Sun H, Li T, Zhuang R, Cai W, Zheng Y. Do renin\u2013angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Medicine (Baltimore). 2017;96:e6394 In this interesting manuscript the Authors evaluate the role of renin-angiotensin inhibitors in patients diagnosed with cancer.","journal-title":"Medicine (Baltimore)"},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","volume":"15","author":"CG Tocchetti","year":"2013","unstructured":"Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15:482\u20139.","journal-title":"Eur J Heart Fail"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","volume":"21","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Cheng S-C, Signoretti S, et al. The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:561\u20138.","journal-title":"Clin Cancer Res"},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer. JAMA Oncol. 2019;5:1020\u20137.","journal-title":"JAMA Oncol"},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/cvr\/cvz058","volume":"115","author":"P Libby","year":"2019","unstructured":"Libby P, Kobold S. Inflammation: a common contributor to cancer, aging, and cardiovascular diseases\u2014expanding the concept of cardio-oncology. Cardiovasc Res. 2019;115:824\u20139.","journal-title":"Cardiovasc Res"},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"J-R Hu","year":"2019","unstructured":"\u2022\u2022 Hu J-R, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854\u201368 This interesting review describes cardiovascular toxicities associated with the administration of immune checkpoint inhibitors, summarizing possible pathophysiological mechanisms involved.","journal-title":"Cardiovasc Res"},{"key":"517_CR45","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","volume":"136","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136:1989\u201392.","journal-title":"Circulation"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"\u2022 Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor t-cells (CAR-T). J Am Coll Cardiol. 2019;74:3099\u2013108 In this recent manuscript the Authors discuss cardiovascular events associated with the administration of Chimeric Antigen Receptor T-Cells.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","volume":"74","author":"P Libby","year":"2019","unstructured":"Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:567\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR48","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"517_CR49","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833\u201342.","journal-title":"Lancet"},{"key":"517_CR50","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","volume":"138","author":"WC Meijers","year":"2018","unstructured":"\u2022\u2022 Meijers WC, Maglione M, Bakker SJL, et al. Heart failure stimulates tumor growth by circulating factors. Circulation. 2018;138:678\u201391 In this interesting paper the Authors demonstrated, in a preclinical model, that the presence of heart failure itself may enhance tumoral growth. Moreover, the Authors identified 5 proteins secreted by the failing heart that might increase the risk of cancer.","journal-title":"Circulation"},{"key":"517_CR51","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","volume":"26","author":"GJ Koelwyn","year":"2020","unstructured":"Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat Med. 2020;26:1452\u20138.","journal-title":"Nat Med"},{"key":"517_CR52","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","volume":"142","author":"S Avraham","year":"2020","unstructured":"\u2022\u2022 Avraham S, Abu-Sharki S, Shofti R, et al. Early cardiac remodeling promotes tumor growth and metastasis. Circulation. 2020;142:670\u201383 In this recent study the Authors demonstrated, in a preclinical model, that cardiac remodeling is associated with higher risk of developing cancer.","journal-title":"Circulation"},{"key":"517_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/ACO.0000000000000335","volume":"29","author":"V Smit-Fun","year":"2016","unstructured":"Smit-Fun V, Buhre WF. The patient with chronic heart failure undergoing surgery. Curr Opin Anaesthesiol. 2016;29:391\u20136.","journal-title":"Curr Opin Anaesthesiol"},{"key":"517_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"\u2022 Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur J Heart Fail. 2017;19:9\u201342 The first international position paper dedicated to the problem of cardiovascular toxicities associated with oncological treatments.","journal-title":"Eur J Heart Fail"},{"key":"517_CR55","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"\u2022 Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893\u2013911 Guidelines published by the American Society of Clinical Oncology addressing the most common cardiovascular complications associated with antineoplastic treatments.","journal-title":"J Clin Oncol"},{"key":"517_CR56","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.6004\/jnccn.2018.0078","volume":"16","author":"CS Denlinger","year":"2018","unstructured":"Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, et al. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16:1216\u201347.","journal-title":"J Natl Compr Cancer Netw"},{"key":"517_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.hfc.2013.10.004","volume":"10","author":"A Newhouse","year":"2014","unstructured":"Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin. 2014;10:295\u2013304.","journal-title":"Heart Fail Clin"},{"key":"517_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/09540261.2013.875891","volume":"26","author":"JL Sotelo","year":"2014","unstructured":"Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. Int Rev Psychiatry. 2014;26:16\u201330.","journal-title":"Int Rev Psychiatry"},{"key":"517_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neubiorev.2018.05.019","volume":"92","author":"M Li","year":"2018","unstructured":"Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev. 2018;92:304\u201317.","journal-title":"Neurosci Biobehav Rev"},{"key":"517_CR60","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","volume":"116","author":"CG Tocchetti","year":"2020","unstructured":"\u2022\u2022 Tocchetti CG, Ameri P, de Boer RA, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116:1820\u201334 In this interesting review the Authors explore recent findings on the link between cardiac cells and cancer. In particular, the Authors discuss the role of cardiac stromal cells and inflammatory cells.","journal-title":"Cardiovasc Res"},{"key":"517_CR61","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"\u2022\u2022 Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945\u201360 In this position statement the Authors discuss, for the first time, which cardiac type of cardiac assessment is necessary to perform at baseline, according to the programmed oncological treatment.","journal-title":"Eur J Heart Fail"},{"key":"517_CR62","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"\u2022\u2022 Pudil R, Mueller C, \u010celutkien\u0117 J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966\u201383 In this position paper the Authors discuss which serum biomarkers need to be dosed in cancer patients to assess cardiac health.","journal-title":"Eur J Heart Fail"},{"key":"517_CR63","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u2022\u2022 \u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the Eur. Eur J Heart Fail. 2020;22:1504\u201324 In this recent paper the Authors discuss the role of different tool for cardiac imaging in the follow-up of cancer patients.","journal-title":"Eur J Heart Fail"},{"key":"517_CR64","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ejhf.1292","volume":"20","author":"N Pareek","year":"2018","unstructured":"\u2022\u2022 Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience. Eur J Heart Fail. 2018;20:1721\u201331 In this study, for the first time, the Authors describe the outcomes and activity of their cardio-oncological service.","journal-title":"Eur J Heart Fail"},{"key":"517_CR65","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.jacc.2019.02.041","volume":"73","author":"SS Hayek","year":"2019","unstructured":"\u2022\u2022 Hayek SS, Ganatra S, Lenneman C, Scherrer-Crosbie M, Leja M, Lenihan DJ, et al. Preparing the cardiovascular workforce to care for oncology patients. J Am Coll Cardiol. 2019;73:2226\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR66","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"517_CR67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ndt\/gfv320","volume":"31","author":"L Cosmai","year":"2016","unstructured":"Cosmai L, Porta C, Gallieni M, Perazella MA. Onco-nephrology: a decalogue: Table 1. Nephrol Dial Transplant. 2016;31:515\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"517_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1056\/NEJMcp050801","volume":"354","author":"BJ Barrett","year":"2006","unstructured":"Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379\u201386.","journal-title":"N Engl J Med"},{"key":"517_CR69","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2004.06.072","volume":"44","author":"J Ezekowitz","year":"2004","unstructured":"Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR70","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","volume":"63","author":"D Farmakis","year":"2014","unstructured":"Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"517_CR71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/eurjhf\/hfp085","volume":"11","author":"MA Mamas","year":"2009","unstructured":"Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676\u201383.","journal-title":"Eur J Heart Fail"},{"key":"517_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1055\/s-0039-1693474","volume":"45","author":"DY Park","year":"2019","unstructured":"Park DY, Khorana AA. Risks and benefits of anticoagulation in cancer and noncancer patients. Semin Thromb Hemost. 2019;45:629\u201337.","journal-title":"Semin Thromb Hemost"},{"key":"517_CR73","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1055\/s-0038-1667001","volume":"118","author":"N Kraaijpoel","year":"2018","unstructured":"Kraaijpoel N, Di Nisio M, Mulder F, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018;118:1439\u201349.","journal-title":"Thromb Haemost"},{"key":"517_CR74","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","volume":"18","author":"F Viganego","year":"2016","unstructured":"Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016;18:52.","journal-title":"Curr Cardiol Rep"},{"key":"517_CR75","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/cncr.22726","volume":"109","author":"CP Gross","year":"2007","unstructured":"Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109:2410\u20139.","journal-title":"Cancer"},{"key":"517_CR76","doi-asserted-by":"publisher","unstructured":"Wang L, Wang F, Chen L, Geng Y, Yu S, Chen Z. Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa779.","DOI":"10.1093\/eurheartj\/ehaa779"},{"key":"517_CR77","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.2016-0412","volume":"22","author":"F Lynce","year":"2017","unstructured":"\u2022\u2022 Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, et al. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist. 2017;22:518\u201325 The first clinical trial designed to evaluate tolerability and efficacy of HER2 inhibitors in patients with heart failure.","journal-title":"Oncologist"},{"key":"517_CR78","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2019.17415","volume":"322","author":"WC Meijers","year":"2019","unstructured":"Meijers WC, Moslehi JJ. Need for multidisciplinary research and data-driven guidelines for the cardiovascular care of patients with cancer. JAMA. 2019;322:1775\u20136.","journal-title":"JAMA"},{"key":"517_CR79","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCULATIONAHA.118.033907","volume":"138","author":"RN Kitsis","year":"2018","unstructured":"Kitsis RN, Riquelme JA, Lavandero S. Heart disease and cancer: are the two killers colluding? Circulation. 2018;138:692\u20135.","journal-title":"Circulation"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-021-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-021-00517-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-021-00517-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T17:54:32Z","timestamp":1672595672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-021-00517-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s11897-021-00517-y","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"19 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"CG Tocchetti has received research funding from Amgen, has received compensation from Alere for service as a consultant, and is listed as an inventor on two heart failure patents. V Mercurio has received research funding from MSD. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}